Fig. 4: Validation of the risk score to predict severe infections and/or death during induction therapy in transplant-eligible NDMM patients in the HO65, EMN02/HO95, and HD7 trials. | Leukemia

Fig. 4: Validation of the risk score to predict severe infections and/or death during induction therapy in transplant-eligible NDMM patients in the HO65, EMN02/HO95, and HD7 trials.

From: Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Fig. 4

Validation of the risk score in the A HO65 trial, B EMN02/HO95 trial, and C HD7 trial. Bar plots show the incidence of severe infections, death, or both during induction therapy according to low-, intermediate-, and high-risk groups. NDMM newly diagnosed multiple myeloma.

Back to article page